A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants (ALEX)
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Sponsor: Hoffmann-La Roche
Listed as NCT02075840, this PHASE3 trial focuses on Non-Small Cell Lung Cancer and remains completed. Sponsored by Hoffmann-La Roche, it has been updated 42 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
42 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Aug 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Jun 2025 — Aug 2025 [monthly]
Completed PHASE3
-
May 2025 — Jun 2025 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 37 earlier versions
-
Mar 2025 — May 2025 [monthly]
Active Not Recruiting PHASE3
-
Dec 2024 — Mar 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
Mar 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE3
-
Dec 2023 — Mar 2024 [monthly]
Active Not Recruiting PHASE3
-
Sep 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE3
-
Jun 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE3
-
Apr 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE3
-
Jan 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE3
-
Sep 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
-
Apr 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE3
-
Feb 2022 — Apr 2022 [monthly]
Active Not Recruiting PHASE3
-
Nov 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE3
-
Sep 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE3
-
May 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE3
-
Feb 2021 — May 2021 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Sep 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE3
-
Jul 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE3
-
May 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE3
-
Feb 2020 — May 2020 [monthly]
Active Not Recruiting PHASE3
-
Nov 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE3
-
Aug 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE3
-
May 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE3
-
Feb 2019 — May 2019 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE3
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Dec 2017 — Apr 2018 [monthly]
Active Not Recruiting PHASE3
-
Sep 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE3
-
Jun 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE3
-
Mar 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Mar 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Aug 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adana, Turkey (Türkiye) , Adelaide, Australia , Alicante, Spain , Ankara, Turkey (Türkiye) , Auckland, New Zealand , Aurora, United States , Bangkok, Thailand , Barcelona, Spain , Bari, Italy , Basel, Switzerland and 71 more locations